This is the element that separates Retatrutide from its predecessors: while GLP-1 and GIP mechanisms reduce intake, the glucagon activation increases energy expenditure
Science 371(6526):265-270
Currently, long-acting GLP-1 agonists dominate the GLP-1 market, and this trend is expected to persist in the coming years
Over the past decade, regulators started approving them as treatments for weight loss first as liraglutide, sold under the brand Saxenda and, more recently, in the form of semaglutide or tirzepatide, under brands like Wegovy and Zepbound
As new AHAs, SGLT2 inhibitors have renoprotection including the following two aspects
Start Your Medical Weight Loss Journey Today